[Experience with the treatment of advanced XXXX in Hungary].

@entity1 @entity4181 @entity788 @entity417 @entity882 @entity5 @entity900 @entity1398 @entity2731 @entity136 @entity1487 @entity1209
In the first phase of this study 34 @entity1 with advanced @entity788 have been treated either with @entity136 / @entity900 or @entity136 / @entity1487 (5FU)/ @entity4181 combination. (Gemzar: 900 mg/m2, @entity900 : 20 mg/m2, @entity1487 : 750 mg/m2). Treatments were continued till @entity5 progression. There was no difference observed between the two protocols in the clinical response rates (PR=65%). On the other hand, a significant difference was found between the two protocols regarding the side effects. In the case of @entity136 / @entity1487 @entity1398 , @entity882 and @entity417 (as well as @entity1209 ) were much less frequent compared to @entity136 / @entity900 combination. Based on these data the efficacy of @entity136 / @entity1487 combination was evaluated in 99 stage III, @entity2731 , N1 and stage IV, @entity2731 , N0-1, M1 @entity788 @entity1 throughout 364 treatment cycles. OR was achieved in 10% while stable disease in 52% of the cases. The average survival period was 8.33 months while the time to progression was 5.75 months. Based on these data we recommend @entity136 / @entity1487 / @entity4181 combination for the treatment of advanced @entity788 .
